NCT04501029View on ClinicalTrials.gov

A Study of Gimatecan (ST1481) in Small Cell Lung Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

October 1, 2022

Study Completion Date

October 1, 2023

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Gimatecan

Patients will receive gimatecan orally at the recommended dose level on day 1-5 every 4 weeks.

Trial Locations (1)

100071

The Fifth Medical Center of General Hospital of the Chinese People's Liberation Army, Beijing

Sponsors
All Listed Sponsors
lead

Lee's Pharmaceutical Limited

INDUSTRY